Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease
Top Cited Papers
Open Access
- 15 March 2008
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 197 (6), 836-845
- https://doi.org/10.1086/528376
Abstract
BackgroundIntravenous ganciclovir administered for 6 weeks improves hearing outcomes in infants with symptomatic congenital cytomegalovirus (CMV) disKeywords
This publication has 30 references indexed in Scilit:
- New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infectionReviews in Medical Virology, 2007
- Cytomegalovirus in the Perilymphatic FluidThe Laryngoscope, 2005
- Detection of Cytomegalovirus (CMV) DNA by Polymerase Chain Reaction Is Associated with Hearing Loss in Newborns with Symptomatic Congenital CMV Infection Involving the Central Nervous SystemThe Journal of Infectious Diseases, 2005
- Detection of Herpesvirus DNAs in Perilymph Obtained from Patients with Sensorineural Hearing Loss by Real‐Time Polymerase Chain ReactionThe Laryngoscope, 2004
- Interval between Births and Risk of Congenital Cytomegalovirus InfectionClinical Infectious Diseases, 2004
- Newborn hearing screening: Will children with hearing loss caused by congenital cytomegalovirus infection be missed?The Journal of Pediatrics, 1999
- Ganciclovir Treatment of Symptomatic Congenital Cytomegalovirus Infection: Results of a Phase II StudyThe Journal of Infectious Diseases, 1997
- Early clinical manifestations and intellectual outcome in children with symptomatic congenital cytomegalovirus infectionThe Journal of Pediatrics, 1987
- Herpesvirus Infections of PregnancyNew England Journal of Medicine, 1985
- Congenital Cytomegalovirus Infection and Sensorineural Hearing LossEar & Hearing, 1984